JPWO2020163871A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020163871A5 JPWO2020163871A5 JP2021546362A JP2021546362A JPWO2020163871A5 JP WO2020163871 A5 JPWO2020163871 A5 JP WO2020163871A5 JP 2021546362 A JP2021546362 A JP 2021546362A JP 2021546362 A JP2021546362 A JP 2021546362A JP WO2020163871 A5 JPWO2020163871 A5 JP WO2020163871A5
- Authority
- JP
- Japan
- Prior art keywords
- drug delivery
- delivery composition
- poly
- injection
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000012377 drug delivery Methods 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 60
- 229920000642 polymer Polymers 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 22
- 238000002347 injection Methods 0.000 claims description 22
- 239000007924 injection Substances 0.000 claims description 22
- 229940124597 therapeutic agent Drugs 0.000 claims description 22
- 239000002775 capsule Substances 0.000 claims description 20
- -1 polypropylenimine Polymers 0.000 claims description 12
- 239000000835 fiber Substances 0.000 claims description 6
- 229920001610 polycaprolactone Polymers 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000004633 polyglycolic acid Substances 0.000 claims description 4
- 229950008885 polyglycolic acid Drugs 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 230000004962 physiological condition Effects 0.000 claims description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 229920002873 Polyethylenimine Polymers 0.000 claims description 2
- 102000007327 Protamines Human genes 0.000 claims description 2
- 108010007568 Protamines Proteins 0.000 claims description 2
- 108091008605 VEGF receptors Proteins 0.000 claims description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 2
- 229960002833 aflibercept Drugs 0.000 claims description 2
- 108010081667 aflibercept Proteins 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 229960003005 axitinib Drugs 0.000 claims description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 229960004891 lapatinib Drugs 0.000 claims description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 229960000639 pazopanib Drugs 0.000 claims description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229920000723 poly(D-arginine) polymer Polymers 0.000 claims description 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 2
- 229920000962 poly(amidoamine) Polymers 0.000 claims description 2
- 229920002246 poly[2-(dimethylamino)ethyl methacrylate] polymer Polymers 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 229940048914 protamine Drugs 0.000 claims description 2
- 229960003876 ranibizumab Drugs 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 description 26
- 239000003361 porogen Substances 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000005245 sintering Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 208000001344 Macular Edema Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 206010025415 Macular oedema Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001523 electrospinning Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 2
- 208000004644 retinal vein occlusion Diseases 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 description 2
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 206010012692 Diabetic uveitis Diseases 0.000 description 1
- 208000001351 Epiretinal Membrane Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- 208000031471 Macular fibrosis Diseases 0.000 description 1
- 208000010164 Multifocal Choroiditis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 208000029977 White Dot Syndromes Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000023564 acute macular neuroretinopathy Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 210000001927 retinal artery Anatomy 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- 201000010594 retinitis pigmentosa 43 Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001982 uveitic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025021232A JP2025093918A (ja) | 2019-02-08 | 2025-02-13 | 治療物質の眼投与のための薬物送達組成物及びその使用法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962803388P | 2019-02-08 | 2019-02-08 | |
| US62/803,388 | 2019-02-08 | ||
| PCT/US2020/017523 WO2020163871A1 (en) | 2019-02-08 | 2020-02-10 | Drug delivery compositions for ocular administration of therapeutics and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025021232A Division JP2025093918A (ja) | 2019-02-08 | 2025-02-13 | 治療物質の眼投与のための薬物送達組成物及びその使用法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022520183A JP2022520183A (ja) | 2022-03-29 |
| JP2022520183A5 JP2022520183A5 (https=) | 2023-03-03 |
| JPWO2020163871A5 true JPWO2020163871A5 (https=) | 2023-03-03 |
| JP7636334B2 JP7636334B2 (ja) | 2025-02-26 |
Family
ID=71947905
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546362A Active JP7636334B2 (ja) | 2019-02-08 | 2020-02-10 | 治療物質の眼投与のための薬物送達組成物及びその使用法 |
| JP2025021232A Pending JP2025093918A (ja) | 2019-02-08 | 2025-02-13 | 治療物質の眼投与のための薬物送達組成物及びその使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025021232A Pending JP2025093918A (ja) | 2019-02-08 | 2025-02-13 | 治療物質の眼投与のための薬物送達組成物及びその使用法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220117888A1 (https=) |
| EP (1) | EP3921420B1 (https=) |
| JP (2) | JP7636334B2 (https=) |
| KR (1) | KR20210138596A (https=) |
| CN (1) | CN113710806A (https=) |
| AU (1) | AU2020219436A1 (https=) |
| BR (1) | BR112021015565A2 (https=) |
| CA (1) | CA3129423A1 (https=) |
| MX (1) | MX2021009526A (https=) |
| WO (1) | WO2020163871A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| WO2021262645A1 (en) * | 2020-06-22 | 2021-12-30 | Ohio State Innovation Foundation | Redox-responsive nanoparticle compositions for ocular delivery of therapeutics |
| US20230392150A1 (en) * | 2020-10-13 | 2023-12-07 | The Asan Foundation | Composition for treating retinal or choroidal diseases, containing acta2 inhibitor as active ingredient |
| EP4317311A4 (en) * | 2021-03-30 | 2025-04-09 | Zeon Corporation | CONTAINER |
| WO2022219089A1 (en) | 2021-04-16 | 2022-10-20 | Fondazione Istituto Italiano Di Tecnologia | Polymeric microparticles for the local treatment of chronic inflammatory diseases |
| EP4358944A4 (en) * | 2021-06-21 | 2025-03-12 | William Marsh Rice University | HIGH-YIELD PREPARATION OF PULSATILE-RELEASE MICROPARTICLES |
| CN113737393B (zh) * | 2021-09-15 | 2022-06-07 | 陕西环保产业研究院有限公司 | 一种静电纺丝纳米纤维膜及其制备方法 |
| US20230355533A1 (en) * | 2022-05-06 | 2023-11-09 | University Of Cincinnati | Biodegradable polycaprolactone capsule for antibody release and degradation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN120478308B (zh) * | 2025-07-17 | 2025-09-09 | 乐比(广州)健康产业有限公司 | 一种基于天然提取物的护眼组合物及其制备工艺 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5516522A (en) * | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| US7838037B2 (en) * | 1999-11-17 | 2010-11-23 | Tagra Biotechnologies Ltd. | Method of microencapsulation |
| WO2006088473A2 (en) * | 2004-04-23 | 2006-08-24 | Panduranga Rao Koritala | Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents |
| CN101137369A (zh) * | 2005-02-09 | 2008-03-05 | 马库赛特公司 | 用于眼治疗的制剂 |
| WO2009012303A2 (en) * | 2007-07-16 | 2009-01-22 | Northeastern University | Therapeutic stable nanoparticles |
| CA2797110C (en) * | 2010-04-22 | 2020-07-21 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
| CA2810842C (en) * | 2010-09-09 | 2018-06-26 | Micell Technologies, Inc. | Macrolide dosage forms |
| US20150037422A1 (en) * | 2012-02-22 | 2015-02-05 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
| HK1204988A1 (en) * | 2012-02-22 | 2015-12-11 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
| CA2867464A1 (en) * | 2012-03-20 | 2013-09-26 | Trustees Of Tufts College | Silk reservoirs for drug delivery |
| WO2015142855A1 (en) * | 2014-03-17 | 2015-09-24 | University Of Virginia Patent Foundation | Compositions and methods for treating retinopathy |
-
2020
- 2020-02-10 AU AU2020219436A patent/AU2020219436A1/en not_active Abandoned
- 2020-02-10 CN CN202080027514.XA patent/CN113710806A/zh active Pending
- 2020-02-10 CA CA3129423A patent/CA3129423A1/en active Pending
- 2020-02-10 JP JP2021546362A patent/JP7636334B2/ja active Active
- 2020-02-10 WO PCT/US2020/017523 patent/WO2020163871A1/en not_active Ceased
- 2020-02-10 EP EP20752549.4A patent/EP3921420B1/en active Active
- 2020-02-10 BR BR112021015565-1A patent/BR112021015565A2/pt unknown
- 2020-02-10 MX MX2021009526A patent/MX2021009526A/es unknown
- 2020-02-10 US US17/428,616 patent/US20220117888A1/en active Pending
- 2020-02-10 KR KR1020217028718A patent/KR20210138596A/ko active Pending
-
2025
- 2025-02-13 JP JP2025021232A patent/JP2025093918A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jiang et al. | Progress on ocular siRNA gene‐silencing therapy and drug delivery systems | |
| JP6371438B2 (ja) | 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート | |
| US10369124B2 (en) | Dendrimer compositions and their use in treatment of diseases of the eye | |
| JP6882186B2 (ja) | スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法 | |
| JP6426194B2 (ja) | 治療用化合物の結晶形態及びその使用 | |
| TWI528963B (zh) | 治療或預防眼科疾病的方法 | |
| CN104363924B (zh) | 用于递送hif‑1抑制剂的控制释放调配物 | |
| JP2023071798A5 (https=) | ||
| JP2009511632A5 (https=) | ||
| CN114081951A (zh) | 治疗眼病的方法 | |
| JP2015508104A5 (https=) | ||
| JPWO2020163871A5 (https=) | ||
| CA2865132A1 (en) | Compositions and methods for ocular delivery of a therapeutic agent | |
| CN113710806A (zh) | 用于眼部施用治疗剂的药物递送组合物以及其使用方法 | |
| JP2021521173A (ja) | 眼内薬物送達用の持続放出微粒子のための方法及び組成物 | |
| CN107206099A (zh) | 用于持续释放抗青光眼剂以控制眼内压的组合物 | |
| US20250092013A1 (en) | Prodrugs of axitinib | |
| JP2013523748A5 (https=) | ||
| TW202237181A (zh) | 治療眼部疾病之方法 | |
| RU2021126314A (ru) | Композиции для доставки лекарственных средств для офтальмологического введения терапевтических средств и способы их применения | |
| TW202448436A (zh) | 含有酪胺酸激酶抑制劑之眼部植入物 | |
| CN108938600B (zh) | 玻璃体内注射的对抗体药物双重保护的微球及其制备方法 | |
| TW202207943A (zh) | 用於長期眼部治療之耐久植入物及微粒 | |
| RU2020136835A (ru) | Способы и композиции для непрерывного высвобождения микрочастиц для доставки лекарственного средства в ткани глаза | |
| CN118141743A (zh) | 一种眼部注射制剂及其应用 |